BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is discontinuing treatment with ICOS agonist feladilimab (GSK3359609) in two Phase II trials for metastatic head and neck squamous cell carcinoma following a recommendation by the independent data monitoring...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

Researchers from Miltenyi Biotec GmbH’s Lentigen unit created trispecific CAR T cells, dubbed duoCAR T cells, directed against CD19, CD20 and CD22 that eliminated antigen-heterogeneous B cell tumors in...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

Though the failure rate of next-generation checkpoints has far out-stripped that of the rare successes, companies have not been scared away from the search for the next blockbuster, or for a way to finally...
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

Twist Bioscience Corp. (NASDAQ:TWST) said it and partner Biotia Inc. received emergency use authorization from FDA for the first hybridization capture-based next-generation sequencing SARS-CoV-2 assay. The SARS-CoV-2 NGS Assay can sequence and surveil the evolution of virus...
BioCentury | Mar 25, 2021
Product Development

BMS achieves rare next-generation checkpoint win with Phase III LAG3 data

BMS continued its successful run in checkpoint inhibitors with the first example of a Phase III survival benefit among mAbs against next-generation targets, but it will be hard to determine where the therapy may fit...
BioCentury | Mar 23, 2021
Finance

Crossovers invest ahead of pre-IPO round, as bispecifics play EpimAb readies to deploy $120M series C

After raising a $120 million series C round co-led by China Merchants Bank International and Mirae Asset Financial Group, EpimAb now turns to executing on its trio of clinical cancer compounds ahead of a pre-IPO...
BioCentury | Mar 20, 2021
Finance

Dallas TIL play leads Friday IPO trio: Data Byte

Less than three years after its launch, Dallas-based TIL specialist Instil led a trio of NASDAQ debuts late this week. Shares of Instil Bio Inc. (NASDAQ:TIL) rose 32% to $26.44 after raising $320 million in...
BioCentury | Mar 17, 2021
Product Development

March 17 Quick Takes: FDA extends review of Rinvoq in psoriatic arthritis; plus Merck, PharmaEssentia, Lilly, Roche and more

AbbVie Inc. (NYSE:ABBV) said FDA extended by three months its review of an sNDA for Rinvoq upadacitinib to treat adult patients with active psoriatic arthritis after the agency had requested additional information on the oral...
BioCentury | Mar 17, 2021
Finance

Vaccitech’s $168M round to fund clinical work on three vaccines using heterologous prime-boost platform

U.K.-based Vaccitech will put its $168 million series B round toward clinical testing of three infectious disease and cancer programs that each use two different vectors for prime-boost delivery, while partner AstraZeneca markets and distributes...
Items per page:
1 - 10 of 1055